Compare Biogen Inc (BIIB) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs VanEck Video Gaming and eSports ETF — how do they compare? Biogen Inc trades at $197.24 (market cap $28.34B), while VanEck Video Gaming and eSports ETF trades at $91.87. The key difference: Biogen Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | ESPO | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $122.30 |
52-Week Low | $122.68 | $85.25 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
ESPO, the VanEck Video Gaming and eSports ETF, trades at $91.78, down 0.62% on the day. Technical indicators show a bullish trend with moving averages signaling strength, though oscillators are neutral and short-term RSI levels suggest overbought conditions. Recent news highlights institutional accumulation and AI-driven profit potential in the gaming sector, with Assetmark Inc. increasing its stake by 35.9% as of its latest 13F filing (SEC, Q1 2026).
The outlook for ESPO is supported by structural growth in digital entertainment and AI efficiency gains, but risks include sector volatility and high valuation multiples. The ETF offers exposure to a high-growth industry, yet investors face concentration risk in gaming stocks and sensitivity to consumer discretionary spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
